Galmed Pharmaceuticals (NASDAQ:GLMD) Earns Sell Rating from Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a research report issued on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Stock Performance

Shares of NASDAQ:GLMD opened at $1.83 on Wednesday. The business’s 50 day simple moving average is $2.64 and its two-hundred day simple moving average is $3.49. The firm has a market cap of $1.18 million, a P/E ratio of -0.11 and a beta of 0.72. Galmed Pharmaceuticals has a 52-week low of $1.75 and a 52-week high of $23.80.

Institutional Trading of Galmed Pharmaceuticals

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC acquired a new position in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned about 3.97% of Galmed Pharmaceuticals as of its most recent SEC filing. Institutional investors own 76.14% of the company’s stock.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.